Status:
WITHDRAWN
Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays
Lead Sponsor:
Kirby Institute
Conditions:
Hepatitis B
Eligibility:
All Genders
18+ years
Brief Summary
Evaluation of novel point of care Hepatitis B diagnostic assays.
Detailed Description
This study aims to evaluate the sensitivity of the following novel assays for evaluation of HBV infection and assessment of treatment eligibility; * GeneXpert HBV DNA via Fingerstick testing, * Dried...
Eligibility Criteria
Inclusion
- Have voluntarily signed the informed consent form.
- 18 years of age or older.
- HBsAg positive
- Part A: Not currently on antiviral therapy for HBV and HBV DNA detectable OR Part B: Stable on HBV antiviral therapy for at least 3 months with HBV DNA \< 20 IU/ml
Exclusion
- 1\) Inability or unwillingness to provide informed consent or abide by the requirements of the study.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04289428
Start Date
January 1 2022
End Date
October 1 2022
Last Update
December 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia, 2010